journal
MENU ▼
Read by QxMD icon Read
search

Lancet Diabetes & Endocrinology

journal
https://www.readbyqxmd.com/read/28215937/long-term-treatment-with-evolocumab-added-to-conventional-drug-therapy-with-or-without-apheresis-in-patients-with-homozygous-familial-hypercholesterolaemia-an-interim-subset-analysis-of-the-open-label-taussig-study
#1
Frederick J Raal, G Kees Hovingh, Dirk Blom, Raul D Santos, Mariko Harada-Shiba, Eric Bruckert, Patrick Couture, Handrean Soran, Gerald F Watts, Christopher Kurtz, Narimon Honarpour, Lihua Tang, Sree Kasichayanula, Scott M Wasserman, Evan A Stein
BACKGROUND: Homozygous familial hypercholesterolaemia is a genetic disorder characterised by substantially raised LDL cholesterol, reduced LDL receptor function, xanthomas, and cardiovascular disease before age 20 years. Conventional therapy is with statins, ezetimibe, and apheresis. We aimed to assess the long-term safety and efficacy of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab in a subset of patients with homozygous familial hypercholesterolaemia enrolled in an open-label, non-randomised phase 3 trial...
February 16, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28215938/limitations-of-cholesterol-lowering-with-pcsk9-inhibitors
#2
Gilbert Thompson
No abstract text is available yet for this article.
February 15, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28196628/research-misconduct-and-the-intergrowth-21st-study
#3
Richard Horton, Sabine Kleinert, Sarah Linklater, Zoë Mullan
No abstract text is available yet for this article.
February 9, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28189656/research-digest-prediabetes-definitions-and-diabetes-prevention
#4
Naveed Sattar, David Preiss
No abstract text is available yet for this article.
February 8, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28189655/the-bare-essentials-ensuring-affordable-access-to-insulin
#5
EDITORIAL
The Lancet Diabetes Endocrinology
No abstract text is available yet for this article.
February 8, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28189654/strategies-to-improve-the-affordability-of-insulin-in-the-usa
#6
Jing Luo, Aaron S Kesselheim, Jeremy Greene, Kasia J Lipska
No abstract text is available yet for this article.
February 8, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28169174/blood-pressure-goals-in-type-2-diabetes-assessing-the-evidence
#7
Peter M Nilsson, Sverre E Kjeldsen
No abstract text is available yet for this article.
February 3, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28159506/elimination-of-iodine-deficiency-disorders-from-the-americas-a-public-health-triumph
#8
Eduardo A Pretell, Elizabeth N Pearce, Sergio A Moreno, Omar Dary, Roland Kupka, Małgorzata Gizak, Jonathan Gorstein, Ruben Grajeda, Michael B Zimmermann
No abstract text is available yet for this article.
January 31, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28131656/integration-of-recent-evidence-into-management-of-patients-with-atherosclerotic-cardiovascular-disease-and-type-2-diabetes
#9
REVIEW
Eberhard Standl, Oliver Schnell, Darren K McGuire, Antonio Ceriello, Lars Rydén
Cardiovascular outcome trials of antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabetes who have, or who are at high risk of, atherosclerotic cardiovascular disease have provided new evidence that has substantially affected the management of cardiovascular risk in these patients. On the basis of proven cardiovascular and renal benefit, the antihyperglycaemic drugs empagliflozin, liraglutide, and semaglutide-the latter being under review for approval by the US Food and Drug Administration and the European Medicines Agency-should be preferentially used as second-line treatments in these patient populations, typically in addition to metformin...
January 25, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28126461/new-country-specific-cvd-risk-charts-recalibrate-and-refine
#10
Andrew Edward Moran
No abstract text is available yet for this article.
January 23, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28126460/laboratory-based-and-office-based-risk-scores-and-charts-to-predict-10-year-risk-of-cardiovascular-disease-in-182-countries-a-pooled-analysis-of-prospective-cohorts-and-health-surveys
#11
Peter Ueda, Mark Woodward, Yuan Lu, Kaveh Hajifathalian, Rihab Al-Wotayan, Carlos A Aguilar-Salinas, Alireza Ahmadvand, Fereidoun Azizi, James Bentham, Renata Cifkova, Mariachiara Di Cesare, Louise Eriksen, Farshad Farzadfar, Trevor S Ferguson, Nayu Ikeda, Davood Khalili, Young-Ho Khang, Vera Lanska, Luz León-Muñoz, Dianna J Magliano, Paula Margozzini, Kelias P Msyamboza, Gerald Mutungi, Kyungwon Oh, Sophal Oum, Fernando Rodríguez-Artalejo, Rosalba Rojas-Martinez, Gonzalo Valdivia, Rainford Wilks, Jonathan E Shaw, Gretchen A Stevens, Janne S Tolstrup, Bin Zhou, Joshua A Salomon, Majid Ezzati, Goodarz Danaei
BACKGROUND: Worldwide implementation of risk-based cardiovascular disease (CVD) prevention requires risk prediction tools that are contemporarily recalibrated for the target country and can be used where laboratory measurements are unavailable. We present two cardiovascular risk scores, with and without laboratory-based measurements, and the corresponding risk charts for 182 countries to predict 10-year risk of fatal and non-fatal CVD in adults aged 40-74 years. METHODS: Based on our previous laboratory-based prediction model (Globorisk), we used data from eight prospective studies to estimate coefficients of the risk equations using proportional hazard regressions...
January 23, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28126459/exercise-management-in-type-1-diabetes-a-consensus-statement
#12
REVIEW
Michael C Riddell, Ian W Gallen, Carmel E Smart, Craig E Taplin, Peter Adolfsson, Alistair N Lumb, Aaron Kowalski, Remi Rabasa-Lhoret, Rory J McCrimmon, Carin Hume, Francesca Annan, Paul A Fournier, Claudia Graham, Bruce Bode, Pietro Galassetti, Timothy W Jones, Iñigo San Millán, Tim Heise, Anne L Peters, Andreas Petz, Lori M Laffel
Type 1 diabetes is a challenging condition to manage for various physiological and behavioural reasons. Regular exercise is important, but management of different forms of physical activity is particularly difficult for both the individual with type 1 diabetes and the health-care provider. People with type 1 diabetes tend to be at least as inactive as the general population, with a large percentage of individuals not maintaining a healthy body mass nor achieving the minimum amount of moderate to vigorous aerobic activity per week...
January 23, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28108304/non-surgical-treatment-of-diabetic-foot-osteomyelitis
#13
Mesut Mutluoglu, Benjamin A Lipsky
No abstract text is available yet for this article.
January 17, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28110912/semaglutide-a-promising-new-glucagon-like-peptide-1-receptor-agonist
#14
André J Scheen
No abstract text is available yet for this article.
January 16, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28110911/efficacy-and-safety-of-once-weekly-semaglutide-monotherapy-versus-placebo-in-patients-with-type-2-diabetes-sustain-1-a-double-blind-randomised-placebo-controlled-parallel-group-multinational-multicentre-phase-3a-trial
#15
Christopher Sorli, Shin-Ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen, Stephen C Bain
BACKGROUND: Despite a broad range of pharmacological options for the treatment of type 2 diabetes, optimum glycaemic control remains challenging for many patients and new therapies are necessary. Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 development for type 2 diabetes. We assessed the efficacy, safety, and tolerability of semaglutide monotherapy, compared with placebo, in treatment-naive patients with type 2 diabetes who had insufficient glycaemic control with diet and exercise alone...
January 16, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28094137/the-artificial-pancreas-ready-for-prime-time
#16
J Hans DeVries
No abstract text is available yet for this article.
January 13, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28094136/day-and-night-glycaemic-control-with-closed-loop-insulin-delivery-versus-conventional-insulin-pump-therapy-in-free-living-adults-with-well-controlled-type-1-diabetes-an-open-label-randomised-crossover-study
#17
Lia Bally, Hood Thabit, Harald Kojzar, Julia K Mader, Jehona Qerimi-Hyseni, Sara Hartnell, Martin Tauschmann, Janet M Allen, Malgorzata E Wilinska, Thomas R Pieber, Mark L Evans, Roman Hovorka
BACKGROUND: Tight control of blood glucose concentration in people with type 1 diabetes predisposes to hypoglycaemia. We aimed to investigate whether day-and-night hybrid closed-loop insulin delivery can improve glucose control while alleviating the risk of hypoglycaemia in adults with HbA1c below 7·5% (58 mmol/mol). METHODS: In this open-label, randomised, crossover study, we recruited adults (aged ≥18 years) with type 1 diabetes and HbA1c below 7·5% from Addenbrooke's Hospital (Cambridge, UK) and Medical University of Graz (Graz, Austria)...
January 13, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28089710/one-small-step-towards-precision-nutrition-by-use-of-metabolomics
#18
Shilpa N Bhupathiraju, Frank B Hu
No abstract text is available yet for this article.
January 12, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28089709/objective-assessment-of-dietary-patterns-by-use-of-metabolic-phenotyping-a-randomised-controlled-crossover-trial
#19
Isabel Garcia-Perez, Joram M Posma, Rachel Gibson, Edward S Chambers, Tue H Hansen, Henrik Vestergaard, Torben Hansen, Manfred Beckmann, Oluf Pedersen, Paul Elliott, Jeremiah Stamler, Jeremy K Nicholson, John Draper, John C Mathers, Elaine Holmes, Gary Frost
BACKGROUND: Accurate monitoring of changes in dietary patterns in response to food policy implementation is challenging. Metabolic profiling allows simultaneous measurement of hundreds of metabolites in urine, the concentrations of which can be affected by food intake. We hypothesised that metabolic profiles of urine samples developed under controlled feeding conditions reflect dietary intake and can be used to model and classify dietary patterns of free-living populations. METHODS: In this randomised, controlled, crossover trial, we recruited healthy volunteers (aged 21-65 years, BMI 20-35 kg/m(2)) from a database of a clinical research unit in the UK...
January 12, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28082082/key-european-guidelines-for-the-diagnosis-and-management-of-patients-with-phenylketonuria
#20
REVIEW
Francjan J van Spronsen, Annemiek Mj van Wegberg, Kirsten Ahring, Amaya Bélanger-Quintana, Nenad Blau, Annet M Bosch, Alberto Burlina, Jaime Campistol, Francois Feillet, Maria Giżewska, Stephan C Huijbregts, Shauna Kearney, Vincenzo Leuzzi, Francois Maillot, Ania C Muntau, Fritz K Trefz, Margreet van Rijn, John H Walter, Anita MacDonald
We developed European guidelines to optimise phenylketonuria (PKU) care. To develop the guidelines, we did a literature search, critical appraisal, and evidence grading according to the Scottish Intercollegiate Guidelines Network method. We used the Delphi method when little or no evidence was available. From the 70 recommendations formulated, in this Review we describe ten that we deem as having the highest priority. Diet is the cornerstone of treatment, although some patients can benefit from tetrahydrobiopterin (BH4)...
January 9, 2017: Lancet Diabetes & Endocrinology
journal
journal
47944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"